Tag Archives: tirzepatide

Innovent QW Oral Small Molecule GLP-1RA Study; Mounjaro CVRR Label Expansion; Pfizer China-Based Berobenatide Obesity Study

Three cardiometabolic-related news items have been observed: Innovent Biologics initiated a Ph1 FIH study of its QW oral small-molecule GLP-1RA (view CT.gov record); Lilly received FDA approval for Mounjaro’s CVRR label expansion based on the SURPASS-CVOT study (view press release); and Pfizer initiated a Ph3 berobenatide study in an obese Chinese population (view CT.gov record). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

AZ Q2 ’26 Earnings; Ex-Dexcom Executive Joins Luna Diabetes; Ascletis Preclinical Tri-Agonist Data; Ionis Pediatric Olezarsen Study; Lexicon Ph3 Sota Study; Veru Ph2b Enobosarm Study

A series of cardiometabolic-related news items has been observed from AstraZeneca, Luna Diabetes, Ascletis Pharma, Ionis Pharmaceuticals, Lexicon Pharmaceuticals, and Veru. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Lilly Ph1b Elora + Tirzep Preliminary Data; Ribo and Madrigal First siRNA Development Milestone; UpDoc FDA Clearance

Three cardiometabolic-related news items have been observed: Lilly released preliminary data from its Ph1b eloralintide + tirzepatide combination study (view abstract), Ribo and Madrigal reached the first milestone in their MASH siRNA partnership (view press release), and UpDoc received FDA clearance for its physician-grade clinical AI platform (view press release ). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Medicare GLP-1 Bridge Program Initiates; Tandem’s t:slim Pump and Abbott’s FreeStyle Libre 3+ Launch in Select UK/EU Markets; Hengrui Posts Ph3 Oral Ribupatide Study in China; Terrestrial Bio Doses First Patient with Needle-Free Sema Patch Technology; Tufts Health Eliminates Coverage for Dexcom CGMs

A series of cardiometabolic-related news items has been observed from The Obesity Action Coalition, Hengrui, Terrestrial Bio, Tandem Diabetes Care, and Tufts Health Direct. Below, FENIX provides highlights and insights into the respective news items.

This content is for Read Less members only.
Already a member? Log in here

ADA 2026 Key Press Releases (June 5)

On the first day of the ADA 2026 conference, six cardiometabolic-related news items have been observed from Tandem, Veru, Gan & Lee, Cigna, Bayer, and Structure Therapeutics. Below, FENIX provides context and analysis for the announcements.

This content is for Read Less members only.
Already a member? Log in here

ProRx FDA Warning Letter; Lilly Partners with UNICEF

Two cardiometabolic-related news items have been observed: FDA issued a warning letter to ProRx regarding GLP-1RA compounding (view FDA letter) and Lilly partnered with UNICEF (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here